CLLS (CLLS) Stock Price & Analysis
CLLS (CLLS) rose 2.05% to USD 2.99 as of June 10, 2026 at 04:55 UTC, according to Nexqual real-time market data.
CLLS last closed at USD 2.93; the session ranged USD 2.89–3.05 on volume of 25,180 shares. Market capitalization is $300.83M, with a 52-week range of USD 1.33–5.48 (NGM). Source: Nexqual, June 10, 2026 at 04:55 UTC.
Key Statistics (as of June 10, 2026 at 04:55 UTC)
| Price | USD 2.99 |
|---|---|
| Change | ▲ 2.05% (up) |
| Previous Close | USD 2.93 |
| Open | USD 3.04 |
| Day Range | USD 2.89 – 3.05 |
| 52-Week Range | USD 1.33 – 5.48 |
| Volume | 25,180 shares |
| Market Cap | $300.83M |
| Exchange | NGM |
Technical Analysis (CLLS)
Nexqual's technical model rates CLLS "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.45 (oversold) |
| vs SMA50 | Below (USD 3.7) |
| MACD | -0.2 (negative) |
Analyst Ratings (CLLS)
Wall Street analysts rate CLLS "Buy" based on 5 analysts, with a mean price target of USD 7.6 (range USD 4–10), per Nexqual as of June 10, 2026 at 04:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 7.6 |
| High Target | USD 10 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (CLLS)
| Next Earnings Date | 2026-08-11 |
|---|---|
| Revenue Estimate | $9.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.18 vs est -0.26 ▲ beat |
| 2025-12-31 | USD -0.24 vs est -0.1 ▼ miss |
| 2025-09-30 | USD 0.02 vs est -0.1 ▲ beat |
| 2025-06-30 | USD -0.22 vs est -0.15 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:55 UTC.
Financials & Fundamentals (CLLS)
| Total Revenue | $75.11M |
|---|---|
| Revenue Growth (YoY) | -37.30% |
| Gross Margin | +100.00% |
| Operating Margin | -333.43% |
| Profit Margin | -89.51% |
| ROE | -76.34% |
| Debt / Equity | 137.41 |
| Current Ratio | 1.52 |
| Total Cash | $185.42M |
| Total Debt | $82.33M |
| Free Cash Flow | $91.42M |
Source: Nexqual, June 10, 2026 at 04:55 UTC.
Financial Health Score (CLLS)
Nexqual rates CLLS's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:55 UTC.
| Growth | Strong — Revenue +52% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $185M cash vs $82M debt, net cash position |
| Cash Flow | Strong — FCF $91M, 132% margin |
| Efficiency | Critical — ROE -76%, ROA -8.4% |
Ownership (CLLS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +16.54% |
| Shares Outstanding | 72.61M |
| Float | 46.69M |
| Short % of Float | +0.64% |
Source: Nexqual, June 10, 2026 at 04:55 UTC.
Leadership (CLLS)
CLLS is led by Andre Choulika (age 60), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 04:55 UTC.
| Co-Founder, CEO & Director | Andre Choulika (age 60) |
|---|---|
| Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director | David J. Sourdive (age 58) |
| CFO & Chief Business Officer | Arthur Stril (age 36) |
| Chief Scientific Officer | Philippe Duchateau (age 62) |
| General Counsel & Secretary of the Board of Directors | Marie-Bleuenn Terrier (age 43) |
Major Backers & Investors (CLLS)
Notable institutional backers of CLLS include B Group, Inc. , UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, Long Focus Capital Management, LLC, according to Nexqual as of June 10, 2026 at 04:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| B Group, Inc. | 4.55% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4.41% |
| Long Focus Capital Management, LLC | 3.81% |
| Nomura Asset Management International Inc | 0.31% |
| Delaware Group Equity Funds IV-Nomura Healthcare Fund | 0.31% |
| LPL Financial LLC | 0.12% |
| Morgan Stanley | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.93% |
Source: Nexqual, June 10, 2026 at 04:55 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | USD 1.9 | ▼ 4.04% |
| ATRA | Atara Biotherapeutics, Inc. | USD 9.77 | ▼ 1.51% |
| SGMO | Sangamo Therapeutics, Inc. | USD 0.15 | ▼ 34% |
| ADAPY | Adaptimmune Therapeutics plc | USD 0.03 | ▼ 20.59% |
| MCRB | Seres Therapeutics, Inc. | USD 6.33 | ▼ 4.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:55 UTC. This page is informational and not investment advice.